Literature DB >> 20471942

DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis.

Katharina Schlereth1, Rasa Beinoraviciute-Kellner, Marie K Zeitlinger, Anne C Bretz, Markus Sauer, Joël P Charles, Fotini Vogiatzi, Ellen Leich, Birgit Samans, Martin Eilers, Caroline Kisker, Andreas Rosenwald, Thorsten Stiewe.   

Abstract

p53 limits the proliferation of precancerous cells by inducing cell-cycle arrest or apoptosis. How the decision between survival and death is made at the level of p53 binding to target promoters remains unclear. Using cancer cell lines, we show that the cooperative nature of DNA binding extends the binding spectrum of p53 to degenerate response elements in proapoptotic genes. Mutational inactivation of cooperativity therefore does not compromise the cell-cycle arrest response but strongly reduces binding of p53 to multiple proapoptotic gene promoters (BAX, PUMA, NOXA, CASP1). Vice versa, engineered mutants with increased cooperativity show enhanced binding to proapoptotic genes, which shifts the cellular response to cell death. Furthermore, the cooperativity of DNA binding determines the extent of apoptosis in response to DNA damage. Because mutations, which impair cooperativity, are genetically linked to cancer susceptibility in patients, DNA binding cooperativity contributes to p53's tumor suppressor activity. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471942     DOI: 10.1016/j.molcel.2010.02.037

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  57 in total

1.  The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein.

Authors:  Michela Muscolini; Elisa Montagni; Vanessa Palermo; Silvia Di Agostino; Wei Gu; Salma Abdelmoula-Souissi; Cristina Mazzoni; Giovanni Blandino; Loretta Tuosto
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

2.  We bonded--now make a decision.

Authors:  Teresa Villanueva
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

Review 3.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

4.  p53 defies convention again: a p53 mutant that has lost tumor suppression but still can kill.

Authors:  James J Manfredi
Journal:  EMBO J       Date:  2019-09-25       Impact factor: 11.598

Review 5.  Physiology of the read-write genome.

Authors:  James A Shapiro
Journal:  J Physiol       Date:  2014-06-01       Impact factor: 5.182

6.  Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity.

Authors:  Shiv K Singh; Nai-Ming Chen; Elisabeth Hessmann; Jens Siveke; Marlen Lahmann; Garima Singh; Nadine Voelker; Sophia Vogt; Irene Esposito; Ansgar Schmidt; Cornelia Brendel; Thorsten Stiewe; Jochen Gaedcke; Marco Mernberger; Howard C Crawford; William R Bamlet; Jin-San Zhang; Xiao-Kun Li; Thomas C Smyrk; Daniel D Billadeau; Matthias Hebrok; Albrecht Neesse; Alexander Koenig; Volker Ellenrieder
Journal:  EMBO J       Date:  2015-01-13       Impact factor: 11.598

7.  Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner.

Authors:  Izumi Kato; Hiroshi Maita; Kazuko Takahashi-Niki; Yoshiro Saito; Noriko Noguchi; Sanae M M Iguchi-Ariga; Hiroyoshi Ariga
Journal:  Mol Cell Biol       Date:  2012-11-12       Impact factor: 4.272

8.  Human cytomegalovirus pUL29/28 and pUL38 repression of p53-regulated p21CIP1 and caspase 1 promoters during infection.

Authors:  John P Savaryn; Justin M Reitsma; Tarin M Bigley; Brian D Halligan; Zhikang Qian; Dong Yu; Scott S Terhune
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

Review 9.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

10.  Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo.

Authors:  Boris Klimovich; Thorsten Stiewe; Oleg Timofeev
Journal:  Cell Cycle       Date:  2019-11-21       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.